BioSpace News Archive

Policy

Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product

Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed generic drug product in a class of medications called antimetabolites.

April 20, 2023

·

2 min read

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, announced it has raised $142 million in combined Series A and B financing.

April 20, 2023

·

6 min read

Empower Clinics Announces Official Launch of Mobile Technology & Communications Platform, PulseIR Powered by Fobi

EMPOWER CLINICS INC announces that the company is officially launching the PulseIR technology platform, a personalized, automated, and data-driven mobile IR solution from the PulseIR subsidiary of Fobi AI.

April 20, 2023

·

6 min read

BioMidwest

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

Veru Inc. announced the sale of its ENTADFI® capsules business for benign prostatic hyperplasia to Blue Water Vaccines, Inc. for $20 million and up to an additional $80 million from sales milestones.

April 20, 2023

·

8 min read

Genetown

Haemonetics Publishes Inaugural Corporate Responsibility Report

Haemonetics Corporation today announced the release of its 2022 Corporate Responsibility Report.

April 20, 2023

·

2 min read

Pharm Country

CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled

CytoSorbents Corporation announces that its pivotal STAR-T randomized, controlled trial has enrolled 80 patients, achieving the second of three key enrollment milestones, and triggering a pre-specified Data and Safety Monitoring Board (DSMB) safety review.

April 20, 2023

·

6 min read

Samsung Bioepis to Present New Data for SB15, a proposed biosimilar to Eylea (aflibercept), at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Samsung Bioepis Co., Ltd. today announced that it will present new data on SB15, a proposed biosimilar to Eylea 1 (aflibercept), at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

April 20, 2023

·

2 min read

Biotech Beach

PreludeDx™ to Present Comparative Analysis of Treatment Recommendations of Black and White DCIS Breast Cancer Patients Using DCISionRT® at ASBrS 2023 Annual Meeting

Prelude Corporation today announced it will be presenting data using DCISionRT ® to examine the decision impact on physician recommendation for adjuvant radiation therapy by race (White vs. Black) in women with ductal carcinoma in situ (DCIS) enrolled in the PREDICT study.

April 20, 2023

·

3 min read

Biotech Bay

Life Sciences Brands Reach Clinically Relevant Audiences with New Veeva Crossix Prime Segments

Veeva Systems (NYSE: VEEV) today announced Veeva Crossix Prime Segments, a new solution helping life sciences brands improve media efficiency and better target patients by reaching more highly-qualified health audiences.

April 20, 2023

·

4 min read

Business

Ionis to hold first quarter 2023 financial results webcast

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 3rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023 financial results.

April 20, 2023

·

1 min read